Estimating the serial intervals of SARS-CoV-2 Omicron BA.4, BA.5, and BA.2.12.1 variants in Hong Kong

被引：5
|
作者：
Guo, Zihao [1 ]
Zhao, Shi [1 ,2 ]
Yam, Carrie Ho Kwan [1 ,2 ]
Li, Conglu [1 ]
Jiang, Xiaoting [1 ]
Chow, Tsz Yu [1 ,2 ]
Chong, Ka Chun [1 ,2 ]
Yeoh, Eng Kiong [1 ,2 ]
机构：
[1] Chinese Univ Hong Kong, Fac Med, JC Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Fac Med, Ctr Hlth Syst & Policy Res, Hong Kong, Peoples R China
来源：
INFLUENZA AND OTHER RESPIRATORY VIRUSES | 2023年 / 17卷 / 02期
基金：
中国国家自然科学基金;
关键词：
COVID-19; disease transmission; Hong Kong; SARS-CoV-2 omicron variant; serial infection interval;
D O I：
10.1111/irv.13105
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Empirical evidence on the epidemiological characteristics of the emerged SARS-CoV-2 variants could shed light on the transmission potential of the virus and strategic outbreak control planning. In this study, by using contact tracing data collected during an Omicron-predominant epidemic phase in Hong Kong, we estimated the mean serial interval of SARS-CoV-2 Omicron BA.4, BA.5, and BA.2.12.1 variants at 2.8 days (95% credible interval [CrI]: 1.5, 6.7), 2.7 days (95% CrI: 2.1, 3.6), and 4.4 days (95% CrI: 2.6, 7.5), respectively, with adjustment for right truncation and sampling bias. The short serial interval for the current circulating variant indicated that outbreak mitigations through contact tracing and case isolation would be quite challenging.
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa
    Wolter, Nicole
    Jassat, Waasila
    Walaza, Sibongile
    Welch, Richard
    Moultrie, Harry
    Groome, Michelle J.
    Amoako, Daniel Gyamfi
    Everatt, Josie
    Bhiman, Jinal N.
    Scheepers, Cathrine
    Tebeila, Naume
    Chiwandire, Nicola
    du Plessis, Mignon
    Govender, Nevashan
    Ismail, Arshad
    Glass, Allison
    Mlisana, Koleka
    Stevens, Wendy
    Treurnicht, Florette K.
    Subramoney, Kathleen
    Makatini, Zinhle
    Hsiao, Nei-yuan
    Parboosing, Raveen
    Wadula, Jeannette
    Hussey, Hannah
    Davies, Mary-Ann
    Boulle, Andrew
    von Gottberg, Anne
    Cohen, Cheryl
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [42] Analytical Sensitivity of Lateral Flow Devices against SARS-CoV-2 Omicron Subvariants BA.4, BA.5, and BA.2.75
    Mackenzie, Charlene
    Batty, Mitchell
    Papadakis, Georgina
    Stevens, Laura
    Yoga, Yano
    Taiaroa, George
    Stefanatos, Helen
    Savic, Ivana
    Tran, Thomas
    Deerain, Joshua
    Prestedge, Jacqueline
    Druce, Julian
    Caly, Leon
    Williamson, Deborah A.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2022, 60 (11)
  • [43] Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa
    Nicole Wolter
    Waasila Jassat
    Sibongile Walaza
    Richard Welch
    Harry Moultrie
    Michelle J. Groome
    Daniel Gyamfi Amoako
    Josie Everatt
    Jinal N. Bhiman
    Cathrine Scheepers
    Naume Tebeila
    Nicola Chiwandire
    Mignon du Plessis
    Nevashan Govender
    Arshad Ismail
    Allison Glass
    Koleka Mlisana
    Wendy Stevens
    Florette K. Treurnicht
    Kathleen Subramoney
    Zinhle Makatini
    Nei-yuan Hsiao
    Raveen Parboosing
    Jeannette Wadula
    Hannah Hussey
    Mary-Ann Davies
    Andrew Boulle
    Anne von Gottberg
    Cheryl Cohen
    Nature Communications, 13
  • [44] BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
    Tartof, Sara Y.
    Slezak, Jeff M.
    Puzniak, Laura
    Hong, Vennis
    Frankland, Timothy B.
    Ackerson, Bradley K.
    Takhar, Harpreet
    Ogun, Oluwaseye A.
    Simmons, Sarah
    Zamparo, Joann M.
    Jodar, Luis
    McLaughlin, John M.
    LANCET INFECTIOUS DISEASES, 2022, 22 (12): : 1663 - 1665
  • [45] What Omicron’s BA.4 and BA.5 variants mean for the pandemic
    Ewen Callaway
    Nature, 2022, 606 : 848 - 849
  • [46] Modeling the Prediction on the Efficacy of a Homologous Third Dose of CoronaVac Against SARS-CoV-2 Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5-China, 2020-2021
    Chen, Xinhua
    Bai, Xufang
    Chen, Xinghui
    Zheng, Nan
    Yang, Juan
    Zhang, Juanjuan
    Yu, Hongjie
    CHINA CDC WEEKLY, 2023, 5 (05): : 103 - +
  • [47] Risk of severe outcomes among SARS-CoV-2 Omicron BA.4 and BA.5 cases compared to BA.2 cases in England
    Aziz, Nurin Abdul
    Nash, Sophie Grace
    Zaidi, Asad
    Nyberg, Tommy
    Groves, Natalie
    Hope, Russell
    Bernal, Jamie Lopez
    Dabrera, Gavin
    Thelwall, Simon
    JOURNAL OF INFECTION, 2023, 87 (01) : E8 - E11
  • [48] Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies
    Bruel, Timothee
    Stefic, Karl
    Nguyen, Yann
    Toniutti, Donatella
    Staropoli, Isabelle
    Porrot, Francoise
    Guivel-Benhassine, Florence
    Bolland, William-Henry
    Planas, Delphine
    Hadjadj, Jerome
    Handala, Lynda
    Planchais, Cyril
    Prot, Matthieu
    Simon-Loriere, Etienne
    Andre, Emmanuel
    Baele, Guy
    Cuypers, Lize
    Mouthon, Luc
    Mouquet, Hugo
    Buchrieser, Julian
    Seve, Aymeric
    Prazuck, Thierry
    Maes, Piet
    Terrier, Benjamin
    Hocqueloux, Laurent
    Schwartz, Olivier
    CELL REPORTS MEDICINE, 2022, 3 (12)
  • [49] Molecular mechanisms responsible for SARS-CoV-2 antibody waning and vaccine escape in Omicron sublineages BA.4 and BA.5
    Hewins, Benjamin
    Richardson, Christopher
    Rubino, Salvatore
    Kelvin, Alyson
    Ostadgavahi, Ali Toloue
    Kelvin, David J.
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2022, 16 (07): : 1122 - 1125
  • [50] Novel SARS-CoV-2 Omicron variants in İstanbul; Rapid Preponderance of BA.2 and BA.5
    Tuyji-Tok, Yesim
    Yucebag, Ebru
    Keles, Ayse Betul
    Kilincarslan, Ayse Ceylan
    Nohut, Okan Kadir
    Salman-Yilmaz, Seda
    Kuskucu, Mert Ahmet
    Midilli, Kenan
    INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY, 2022, 4 (03): : 192 - 198
12345